CancerX Accelerator

CancerX Accelerator’s 2026 cohort was a participation cycle operated through a public-private partnership whose hosts CancerX identifies as Advocate Health and Moffitt Cancer Center. The application FAQ called for a validated product or solution ready to scale, a completed clinical proof-of-concept pilot involving at least 50 patients living with cancer, at least 10 full-time employees or equivalent, and a designated liaison for engagement with the selection team. Applicants also needed a digital solution related to one of the FAQ’s four theme areas.

The planned experience combined monthly virtual curriculum sessions with four in-person events over five months. The FAQ planned the first in-person event at Moffitt Cancer Center in Tampa, Florida. CancerX described strategic partnership opportunities with healthcare organizations and investors, access to a digital-health and oncology mentorship network, and customized programming. The FAQ said champions would meet with participating finalists to discuss their goals and approach. CancerX announced that 12 companies were selected for the third cohort in January 2026; this establishes selection, not completion. The FAQ and recruitment announcement differ on the planned end month, and the FAQ states that results are not guaranteed.

The 2026 application FAQ called for a validated product or solution ready to scale, at least one completed clinical proof-of-concept pilot involving at least 50 patients living with cancer, and a company with at least 10 full-time employees or equivalent. Applicants needed a digital solution related to one of the FAQ’s four theme areas and a designated liaison to engage with the selection team. Acceptance also required strong interest from at least two champions.

CancerX described strategic partnership opportunities with healthcare organizations and investors, access to an expert digital-health and oncology mentorship network, and customized programming combining virtual and in-person events. The application FAQ said each champion would meet with participating finalists to discuss their goals and approach. These are described opportunities and planned activities; the FAQ does not guarantee results.

Applications for the 2026 cohort opened September 9, 2025, and closed October 28, 2025. The application FAQ scheduled pitch days for November 14 and November 21, 2025. CancerX announced 12 selected companies on January 12, 2026. The FAQ scheduled the accelerator from February through June 2026, while the recruitment announcement listed programming through July 2026, leaving the actual end date unresolved. The application guide described a five-month commitment.